Actavis unit yanks another 94K Bystolic bottles as recall expands

Actavis ($ACT) nabbed a big portfolio of branded products when it bought Forest Laboratories ($FRX) earlier this year. But it also inherited a quality-control problem. Forest expanded on a recall of Bystolic, one of its key drugs, adding another lot of more than 94,000 cartons of the blood pressure meds to the nationwide retrieval. It is the second recall in three months. Report

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.